A multicenter, single-arm, open study of neoadjuvant or conversion atezolizumab in combination with chemotherapy in resectable small cell lung cancer (neoSCI) (Cohort Study).

ABSTRACT:

Background

This study aimed to investigate the prospects of using chemotherapy in combination with atezolizumab in the neoadjuvant or conversion treatment of small cell lung cancer (SCLC).

Methods

Prior to surgery, untreated patients with limited-stage SCLC received 3 cycles of neoadjuvant or conversion atezolizumab combined with chemotherapy of etoposide and platinum. The primary endpoint of the trial was pathological complete response (pCR) in the per-protocol (PP) cohort. In addition, safety was assessed based on treatment-related adverse events (AEs) and postoperative complications.

Results

Overall, thirteen of seventeen patients (including fourteen males and three females) underwent surgery. In the PP cohort, pCR and MPR were observed in eight (8/13, 61.5%) and t

SUBMITTER: Duan H 

PROVIDER: S-EPMC10498862 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature